TL;DR
The recent genetic strategies, such as targeted virulent gene deletions, CRISPR-Cas inactivation, and viral codon deoptimization approaches used to attenuate or inactivate Dengue viruses specifically are explored.
Dengue fever is one of the most serious public health issues in tropical and subtropical regions, transmitted by the mosquito Aedes. There are four serotypes of the Dengue virus [DENV, types 1-4]. Every year, millions of people contract dengue infection. Symptoms range from fever to the more complicated condition of he...
This review examines the roles of four key frontiers, including organoid models, gene editing, AI-driven molecular design, and synthetic biology, and discusses how these technological frontiers contribute to disease modeling, target discovery, molecular design, and translational innovation.
Dengue is among the fastest-growing mosquito-borne viral infections worldwide and continues to pose a major public health challenge because no approved antiviral treatment is available. As a result, vaccination has become a cornerstone of dengue prevention. Several vaccine candidates have progressed through clinical de...
This review examines the principles and applications of target-based antiviral drug development against human respiratory viruses, emphasizing the identification and exploitation of conserved viral and host targets.
Proof of concept is provided for the use of codon deoptimization (CD) as a rational strategy to generate attenuated RVFV, for the development of next-generation vaccines against this zoonotic threat.
Dengue control is entering a period in which vaccination, direct-acting antiviral development and increasingly sophisticated diagnostics can no longer be evaluated as separate technical domains. Vaccine performance is shaped by baseline dengue serostatus, circulating serotype and duration of follow-up; antiviral effica...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
